BIO-TECHNE Corp — Form 8-K
Filed September 23, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 95/100
What the filing says
Bio-Techne Corporation shareholders voted to approve the definitive merger agreement with Merck KGaA, Darmstadt, Germany on September 23, 2026. The Hart-Scott-Rodino antitrust waiting period expired September 18, 2026. Bio-Techne expects the transaction to close by late 2026 or early 2027, subject to remaining regulatory approvals and customary closing conditions. The filing does not disclose the acquisition price or other financial terms.
Why this rating
Shareholder approval + HSR clearance achieved for a transformational $9B+ company acquisition. Closure of entire business imminent—this is a going-concern event materially altering the company's trajectory.
Price action (we called it neutral)
before filing · preread $72.52 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.